伏美替尼治疗EGFR突变阳性非小细胞肺癌EGFR-TKI耐药患者的临床观察

目的 分析伏美替尼治疗表皮生长因子受体（EGFR）突变阳性非小细胞肺癌表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）耐药患者的临床疗效。方法 选取2021年3月—2021年9月武警四川总队医院收治的EGFR突变阳性非小细胞肺癌EGFR-TKI耐药患者76例作为研究对象，并随机分为对照组（给予培美曲塞治疗，37例）和实验组（给予伏美替尼治疗，39例）。比较两组患者近期临床疗效、肿瘤标志物、血清基质金属蛋白酶-9（MMP-9）及基质金属蛋白酶抑制剂-1（TIMP-1）水平。比较两组患者安全性和预后生存情况。结果 实验组客观缓解率高于对照组（P <0.05）。实验组治疗前后CEA、CA19-9、CYFRA21-1、MMP-9、TIMP-1的差值大于对照组（P <0.05）。两组患者不良反应发生率比较，差异无统计学意义（P >0.05）。实验组存活率高于对照组（P <0.05）。结论 伏美替尼治疗EGFR突变阳性非小细胞肺癌EGFR-TKI耐药患者可提高临床疗效，降低肿瘤标志物和血清MMP-9、TIMP-1水平，延长患者生存时间且安全性良好。

Efficacy of furmonertinib in the treatment of EGFR-TKI-resistant patients with EGFR mutation-positive non-small cell lung cancer

Objective To observe the efficacy of furmonertinib in the treatment of epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer patients with EGFR-tyrosine kinase inhibitor (EGFR-TKI) resistance.Methods A total of 76 patients with EGFR mutation-positive non-small cell lung cancer and EGFR-TKI resistance who were admitted to our hospital from March 2021 to September 2021 were selected and divided into the control group (treated with pemetrexed, 37 cases) and the test group (treated with furmonertinib, 39 cases) by random number table method. The short-term clinical efficacy, and serum levels of tumor markers, matrix metalloproteinase-9 (MMP-9) and TIMP metallopeptidase inhibitor 1 (TIMP-1) were compared between the two groups. The safety and prognosis of patients in the two groups were also compared.Results The objective response rate was higher in the test group than that in the control group (P < 0.05). The differences in the levels of CEA, CA19-9, CYFRA21-1, MMP-9 and TIMP-1 before and after the treatment in the test group were greater than those in the control group (P < 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P > 0.05). The survival rate of the test group was higher than that of the control group (P < 0.05).Conclusions Furmonertinib may improve the clinical efficacy in the treatment of EGFR mutation-positive non-small cell lung cancer patients with EGFR-TKI resistance. It reduces the levels of tumor markers and serum levels of MMP-9 and TIMP-1, and prolongs the survival time of patients with no safety concerns.